Jose Fulla - Grifols SA CEO of Diagnostic Industrial Group
CEO
Jose Fulla is CEO of Diagnostic Industrial Group of Grifols SA since 2017.
Tenure | 7 years |
Phone | 34 93 571 02 21 |
Web | https://www.grifols.com |
Grifols SA Management Efficiency
The company has return on total asset (ROA) of 0.0155 % which means that it generated a profit of $0.0155 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0182 %, meaning that it generated $0.0182 on every $100 dollars invested by stockholders. Grifols SA's management efficiency ratios could be used to measure how well Grifols SA manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 6.1 B in total debt with debt to equity ratio (D/E) of 1.14, which is about average as compared to similar companies. Grifols SA has a current ratio of 2.63, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Grifols SA until it has trouble settling it off, either with new capital or with free cash flow. So, Grifols SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Grifols SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Grifols to invest in growth at high rates of return. When we think about Grifols SA's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | CEO Age | ||
Bruno Strigini | Novartis AG ADR | N/A | |
Richard Saynor | Novartis AG ADR | 57 | |
Osamu Nagayama | Roche Holding Ltd | 69 | |
Pascal Soriot | AstraZeneca PLC ADR | 60 | |
Chris Ilsley | Novartis AG ADR | N/A | |
Francesco Balestrieri | Novartis AG ADR | N/A | |
Emma Walmsley | GlaxoSmithKline PLC ADR | 55 | |
Severin Schwan | Roche Holding Ltd | 56 | |
William Anderson | Roche Holding Ltd | 57 | |
Andrew Witty | GlaxoSmithKline PLC ADR | 50 | |
Michael Heuer | Roche Holding Ltd | 64 | |
PerOlof Attinger | Roche Holding Ltd | 58 | |
Elizabeth Barrett | Novartis AG ADR | 56 | |
Brian McNamara | GlaxoSmithKline PLC ADR | 49 | |
Michael Ball | Novartis AG ADR | 62 | |
Paul Hudson | Novartis AG ADR | 51 | |
Joseph Jimenez | Novartis AG ADR | 58 | |
Olivier Brandicourt | Sanofi ADR | 62 | |
Deborah Waterhouse | GlaxoSmithKline PLC ADR | N/A |
Management Performance
Return On Equity | 0.0182 | |||
Return On Asset | 0.0155 |
Grifols SA Leadership Team
Elected by the shareholders, the Grifols SA's board of directors comprises two types of representatives: Grifols SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Grifols. The board's role is to monitor Grifols SA's management team and ensure that shareholders' interests are well served. Grifols SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Grifols SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Antonio Pares, Director of Planning and Control | ||
Peter Allen, Chairman of Hospital OPS Division | ||
Carsten Schroeder, President Of The Diagnostic Division | ||
Albert Roura, CEO of Laboratorios Grifols SA | ||
Jose Garcia, Director General De Laboratorios Grifols | ||
Lafmin Morgan, President Of The Bioscience And Hospital Division | ||
Juan Roura, Vice President of Production, Executive Director | ||
Eva Tubau, Chief Scientific Officer | ||
Anna Lluch, Independent Director | ||
Carlos Fernandez, Deputy Industrial Vice President | ||
Jose Gras, Director, Representative of Thorthol Holdings BV | ||
Maria Llano, Chief Officer | ||
Edgar Jannotta, Independent Director | ||
Vicente Torre, CTO | ||
Mateo Humbert, Director of Human Resources | ||
Montserrat Calvo, Chief Administrative Officer, Controller | ||
Montserrat Llamas, Chief Officer | ||
Ramon Roca, Vice-President of Marketing and Sales and Executive Director | ||
Vctor Deu, CoCEO Director | ||
David Bell, Vice President of Corporate Operations and Development of Grifols Inc and United States Subsidiaries | ||
Victor Deu, Co-CEO, Executive Director | ||
Luis Bobadilla, Independent Director | ||
Inigo Mardones, Director | ||
Thomas Glanzmann, Director | ||
Carina Lazaro, Independent Director | ||
Joel Abelson, President of North America Commercial Division of Grifols Inc | ||
Steven Mayer, Director | ||
Jose Fulla, CEO of Diagnostic Industrial Group | ||
Javier Ribes, CEO of Instituto Grifols SA | ||
Alfredo Guerra, CFO and Corporate VP | ||
Raimon Roura, Non-Member Secretary of the Board | ||
Miguel Montblanch, Chariman of Global Operations Network | ||
Victor Roura, Chairman, CEO and President and Member of Appointments and Remuneration Committee | ||
Brett Ingersoll, Director | ||
Shinji Wada, President of Plasma Centers of Grifols Inc | ||
Tomas Gelabert, Director | ||
Nuria Lapea, Risk Treasury | ||
M Tubau, Co Affairs | ||
Steven JD, Ex Chairman | ||
Marla Salmon, Independent Director | ||
Nuria Barnes, Non-Member Assistant Secretary of the Board | ||
Gregory Rich, President of Grifols Inc and Subsidiaries in the US | ||
Belen Morenes, Independent Director | ||
Nuria Lapena, Director of Shareholder and Investor Relations |
Grifols Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Grifols SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0182 | |||
Return On Asset | 0.0155 | |||
Profit Margin | 0.01 % | |||
Operating Margin | 0.09 % | |||
Current Valuation | 16.07 B | |||
Shares Outstanding | 422.18 M | |||
Shares Owned By Insiders | 30.57 % | |||
Shares Owned By Institutions | 30.49 % | |||
Price To Earning | 9.52 X | |||
Price To Book | 1.04 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Grifols SA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Grifols SA's short interest history, or implied volatility extrapolated from Grifols SA options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Grifols Pink Sheet analysis
When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Fundamental Analysis View fundamental data based on most recent published financial statements |